Abstract
Corticotropin-releasing hormone (CRH) is produced in response to stress. This hormone plays a key role in mediating neuroendocrine, behavioral, and autonomic responses to stress. The CRH receptor 1 (CRHR1) is expressed in multiple brain regions including the cortex and hippocampus. Previous studies have shown that activation of CRHR1 by CRH results in the rapid loss of dendritic spines. Exchange protein directly activated by cAMP (EPAC2, also known as RapGEF4), a guanine nucleotide exchange factor (GEF) for the small GTPase Rap, has been linked with CRHR1 signaling. EPAC2 plays a critical role in regulating dendritic spine morphology and number in response to several extracellular signals. But whether EPAC2 links CRHR1 with dendritic spine remodeling is unknown. Here we show that CRHR1 is highly enriched in the dendritic spines of primary cortical neurons. Furthermore, we find that EPAC2 and CRHR1 co-localize in cortical neurons. Critically, short hairpin RNA-mediated knockdown of Epac2 abolished CRH-mediated spine loss in primary cortical neurons. Taken together, our data indicate that EPAC2 is required for the rapid loss of dendritic spines induced by CRH. These findings identify a novel pathway by which acute exposure to CRH may regulate synaptic structure and ultimately responses to acute stress.
Introduction
Corticotropin-releasing hormone (CRH) is a 41-amino acid neuropeptide that is an important regulator of hormonal, behavioral, and autonomic responses to stress (Henckens et al., 2016; Sanders & Nemeroff, 2016). CRH is expressed in discrete regions within the central nervous system (Grammatopoulos, 2012; Henckens et al., 2016), and CRH receptors are expressed in multiple brain regions (Henckens et al., 2016). The CRH receptor type 1 (CRHR1) is a 7-transmembrane G-protein coupled receptor that transmits signals via the Gsα-mediated regulation of cAMP (Traver et al., 2006; Grammatopoulos, 2012). The CRH peptide has been shown to be released locally within the amygdala, hippocampus, and cortex, and to be involved in the modulation of cognition, including memory and anxiety, during stress (Henckens et al., 2016; Sanders & Nemeroff, 2016). Moreover, chronic exposure to CRH may have long-lasting detrimental effects (Maras & Baram, 2012; Henckens et al., 2016). Interestingly, acute exposure to CRH also results in the loss of dendritic spine on CA1 hippocampal neurons; this effect could be blocked by CRHR1 antagonism (Chen et al., 2008; Andres et al., 2013). CRH-mediated spine loss in the hippocampus have been linked with RhoA signaling (Chen et al., 2013), as well as a nectin-3/afadin complex (Wang et al., 2013).
Exchange protein directly activated by cAMP 2 (EPAC2, also known as cAMP-GEFII or RapGEF4) is a signaling protein present in forebrain postsynaptic densities (Woolfrey et al., 2009; Srivastava et al., 2012). This protein has been shown to be involved in a range of cognitive function including social behaviors (Srivastava et al., 2012) and learning and memory (Yang et al., 2012). Interestingly, recent studies have also implicated the EPAC2 gene in the response to stress, anxiety, and depression (Zhou et al., 2016; Aesoy et al., 2018). Interestingly, EPAC2 has been suggested to mediate CRH/CRHR1 coupling to the ERK-MAPK pathway (Traver et al., 2006; Grammatopoulos, 2012; Inda et al., 2016). Moreover, EPAC2 has also been shown to regulate dendritic spine morphology, motility, and density (Woolfrey et al., 2009; Srivastava et al., 2012). Based on these previous studies, we hypothesized that EPAC2 might play a role in CRH/CRHR1-mediated spine alterations.
Here we investigated the presence of CRHR1 at dendritic spines of primary cortical neurons. We examined whether CRHR1 and EPAC2 co-localized within cortical neurons and whether acute exposure to CRH altered spine density in cortical neurons. Finally, we tested whether EPAC2 was required for CRH-mediated spine loss.
Materials and Methods
Reagents
CRH was purchased from Bio-Techne (“CRF”, Cat. No. 1151). Antibodies used: green fluorescent protein (GFP) mouse monoclonal (MAB3580; Merck; 1:1,000); EPAC2 monoclonal (A-7, Santa Cruz, 1:200); CRHR1 polyclonal (EB08035; Everest Biotech; 1:500). Control and Epac2-shRNA constructs, expressing shRNA sequences and GFP, were previously described (Woolfrey et al., 2009).
Neuronal culture and transfections
Cortical neuronal cultures, derived from both sexes, were prepared from E18 Sprague-Dawley rat embryos (Srivastava et al., 2011). Animals were habituated for 3 days before experimental procedures: experiments were carried out in accordance with the Home Office Animals (Scientific procedures) Act, United Kingdom, 1986. Cells were plated onto 18 mm glass coverslips (No 1.5), coated with poly-D-lysine (0.2 mg/mL, Sigma), at a density of 3×105/well equal to 857/mm2. Neurons were cultured in feeding media: neurobasal medium (21103049) supplemented with 2% B27 (17504044), 0.5 mM glutamine (25030024) and 1% penicillin:streptomycin (15070063) (Life Technologies). Neuronal cultures were maintained in the presence of 200 µM D,L-amino-phosphonovalerate (APV, ab120004, Abcam) beginning on day 4 in vitro (DIV 4) in order to maintain neuronal health for long-term culturing (Srivastava et al., 2011).
Primary cortical neurons were transfected with eGFP, control (scram-)RNAi or Epac2-RNAi at DIV 21, using Lipofectamine 2000 (Life Technologies). Briefly, 2-4 µg of plasmid DNA was mixed with Lipofectamine 2000 and incubated for 4 hours, before being replaced with fresh feeding media. Transfections were allowed to proceed for 2-5 days, after which cells were used for pharmacological treatment or immunocytochemistry.
Pharmacological treatments of neuronal cultures
Treatments were performed in artificial cerebral spinal fluid (aCSF): (in mM) 125 NaCl, 2.5 KCL, 26.2 NaHCO3, 1 NaH2PO4, 11 glucose, 5 HEPES, 2.5 CaCl2, 1.25 MgCl2, and 0.2 APV. CRH was dissolved in H2O (10 mM), serially diluted to 1 µM in aCSF and applied directly to neuronal cultures at a final concentration of 100 nM. Final amount of H2O was < 0.01%; vehicle control was made up of H2O lacking compound. Treatments time was 30 minutes.
Immunocytochemistry
Neurons were washed in phosphate-buffered saline (PBS), fixed in 4% formaldehyde/4% sucrose PBS for 10 minutes at room temperature, followed by incubation in methanol pre-chilled to −20°C for 10 minutes at 4°C. Fixed neurons were then permeabilized and blocked simultaneously (2% normal goat serum, 5425S, New England Biolabs, and 0.1% Triton X-100) before incubation in primary antibody solutions overnight and subsequent incubation with secondary antibodies the following day.
Quantitative analysis of spine morphologies and immunofluorescence
Confocal images of double-stained neurons were acquired with a Leica SP-5 confocal microscope using a 63x oil-immersion objective (Leica, N.A. 1.4) as a z-series. Two-dimensional maximum projection reconstructions of images were generated and linear density calculated using ImageJ/Fiji (https://imagej.nih.gov/ij/) (Srivastava et al., 2011). Morphometric analysis was performed on spines from two dendrites (secondary or tertiary branches), totaling 100 µm, from each neuron. The linear density and total gray value of each synaptic protein cluster were measured automatically using MetaMorph Software (Molecular Devices). Cultures directly compared were stained simultaneously and imaged with the same acquisition parameters. For each condition, 13-18 neurons from at least 3 separate experiments were used. Analyses were performed blind to condition and on sister cultures. In the green/magenta color scheme, co-localization is indicated by white overlap.
Statistical analysis
All statistical analysis was performed in GraphPad. Differences in quantitative immunofluorescence and dendritic spine number were probed by one-way ANOVAs with Tukey correction for multiple comparisons. Error bars represent standard deviations in Figure 1D and standard errors of the mean in Figure 2B-C.
Results
CRHR1 localizes to dendritic spines and co-localizes with EPAC2 in cortical neurons
Previous studies have shown that CRHR1 localizes in dendritic spines of CA1 hippocampal neurons (Chen et al., 2010; Andres et al., 2013). Whilst CRHR1 expression in cortical regions has been reported, whether or not this receptor is expressed in spines of cortical neurons has yet to be established. To investigate this, we immunostained DIV 25 primary cortical neurons expressing GFP for CRHR1 (Figure 1A). Immunoreactive puncta for CRHR1 could be observed within the somato-dendritic compartment of neurons. In individual neurons, CRHR1 clustered along dendrites, with prominent puncta evident near or at the base of dendritic spines (red arrowheads) and distinct clusters within spine heads (red arrows, Figure 1A). To determine whether CRHR1 localized to a specific subpopulation of dendritic spines, we classified spines containing CRHR1 according to dendritic spine area. Spines with an area of less than 1.0 µm were designated as “small”, whereas spines with an area of larger than 1.0 µm were designated as “large”. Of the spines that contained CRHR1, the majority (∼60%) were large (Figure 1B). These data indicate that in primary cortical neurons, CRHR1 is enriched at synapses of a subset of large dendritic spines.
Pharmacological studies have suggested that CRHR1 may signal via the EPAC proteins (Traver et al., 2006; Grammatopoulos, 2012; Inda et al., 2016). EPAC2 is the predominant EPAC protein expressed in cortical neurons with mature dendritic morphology, and is highly enriched in dendritic spines (Woolfrey et al., 2009). Therefore, we reasoned that CRHR1 may colocalize with EPAC2 in cortical neurons. Endogenous EPAC2 and CRHR1 were detected by immunofluorescence using specific antibodies in DIV 23 primary cortical neurons. As previously described, EPAC2 was present along dendrites and in spines (Figure 1C) (Woolfrey et al., 2009). Consistent with our data describing the localization of CRHR1 in cortical neurons, CRHR1 was also observed along dendrites and spine-like structures. Moreover, CRHR1 and EPAC2 were found to co-localize along dendrites (red arrowheads) and in a subset of spine-like structures (red arrows) (Figure 1C). Quantification of co-localization revealed that ∼70% of CRHR1 puncta co-localized with EPAC2, whereas only ∼40% of EPAC2 puncta colocalized with CRHR1 (Figure 1D). Taken together, these data indicate that CRHR1 is ideally positioned to interact with and signal via EPAC2 at synapses.
CRH-mediated spine loss is dependent on EPAC2 in cortical neurons
As our data indicated that CRHR1 co-localizes with EPAC2, we hypothesized that CRH-mediated spine loss may be mediated by this Rap GEF. To test this, we treated primary cortical neurons expressing a control shRNA (scram-RNAi)or an shRNA specific for Epac2 (Epac2-RNAi; Supplemental Figure 1) (Woolfrey et al., 2009) with CRH. Consistent with previous reports, 30 minutes of CRH exposure resulted in a significant loss of dendritic spines (Figure 2). Epac2-RNAi alone had no effect on spine linear density;.however, treatment of cortical neurons expressing Epac2-RNAi with CRH no longer resulted in a reduction in dendritic spine density (Figure 2B). Examination of spine morphology revealed that CRH treatment resulted in an overall decrease in spine size; this effect was no longer evident in neurons treated with CRH and expressing Epac2-RNAi (Figure 2C). Taken together these data suggest that CRH signals via EPAC2 to induce the rapid loss of dendritic spines.
Discussion
Previous studies have shown that CRH signaling via CRHR1 can cause the rapid and persistent loss of dendritic spines in hippocampal neurons (Chen et al., 2008; Chen et al., 2010). This loss of spine density is further correlated with memory defects associated with acute stress (Chen et al., 2010). In this study, we build upon these findings to show that in primary cortical neurons, CRHR1 localizes to synapses in dendritic spines, where it co-localizes with the Rap GEF EPAC2. Moreover, acute exposure to CRH resulted in the rapid loss of dendritic spines, an effect that was attenuate by the knockdown of Epac2. Taken together, these data indicate that CRH signaling via a CRHR1/EPAC2-dependent signaling pathway is responsible for the actions of this hormone in regulating the density of dendritic spines and contributing to acute stress effects.
Stress is a biologically important event that can have both positive and negative effects on brain function. Multiple lines of evidence have demonstrated that stress can induce a range of morphological changes in neuronal and synaptic structure. CRH is released in response to stress, and recent findings have shown that blocking the CRHR1 receptor was sufficient to block stress-induced spine loss (Chen et al., 2008; Chen et al., 2010). Interestingly, in hippocampal neurons, CRH-mediated spine loss on CA1 hippocampal neurons is dependent on synaptic-activity (Andres et al., 2013). Data indicates that EPAC2 is required for CRH-dependent spine loss on cortical neurons. Whether CRH acts via the regulation of both EPAC2 and synaptic-activity to induce spine loss, or whether these are independent mechanisms dependent on cell type is currently unclear.
Moreover, recent studies have shown that EPAC2 expression is increased in response to acute stress, and is involved in controlling cellular responses to acute stress (Aesoy et al., 2018). Indeed, animals lacking the EPAC proteins display increased anxiety and depressive behaviors (Srivastava et al., 2012; Yang et al., 2012). Interestingly, our previous work has shown that EPAC2 is a key regulator of dendritic spine structural plasticity in response to a number of extrinsic stimuli (Woolfrey et al., 2009; Srivastava et al., 2012). Consistent with these studies, our current data indicate that EPAC2 is required for mediating CRH-induced spine loss. In hippocampal neurons, CRH-mediated spine loss is dependent on RhoA activity (Chen et al., 2013) as well as a nectin-3/afadin complex (Wang et al., 2013). Afadin is a direct target of Epac-Rap1 signaling and, a Rap1-afadin complex has been shown to regulate RhoA activity and cytoskeletal dynamics in endothelia cells (Birukova et al., 2013). Thus, an intriguing possibility is that these signaling molecules cooperate to induced spine loss following CRH-activity. Interestingly, it has recently been shown that CRHR1 engages atypical soluble adenylate cyclase to signal to EPAC proteins (Inda et al., 2016) indicating an indirect interaction between these 2 proteins.
It is also interesting to note that EPAC2 has been associated with anxious and depressive behaviors as well as in stress responses (Yang et al., 2012; Zhou et al., 2016; Aesoy et al., 2018). Furthermore, EPAC2 plays an important role in cognitive function, including learning and memory (Srivastava et al., 2012; Yang et al., 2012). Given that CRH and CRHR1 have strongly been implicated in stress-mediated effects on these cognitive functions (Maras & Baram, 2012; Henckens et al., 2016), the data presented in this study suggest that a CRH/CRHR1/EPAC2 pathway may be critical for these effects. Taken together, these data reveal a novel mechanism involving EPAC2, by which CRH-induced rapid modulation of dendritic spines can occur. Future studies will be required to understand whether and how this pathway is involved in mediating responses to chronic stress at both the morphological and behavioral levels.
Conflict of Interest Statement
The authors have no competing interests to declare.
Author Contributions
P.P and D.P.S. were responsible for the conception and design of the work. Z.X. and D.P.S. were responsible for data collection, analysis, and interpretation.
Drafting and critical revision of the article was carried out by P.P. and D.P.S.
Final approval of the version to be published was confirmed by Z.X., P.P. and D.P.S.
Data Accessibility Statement
All primary data are available upon request from the authors.
Abbreviations
- aCSF
- artificial cerebral spinal fluid;
- APV
- amino-phosphonovalerate;
- CRH
- corticotropin-releasing hormone;
- CRHR1
- corticotropin-releasing hormone receptor 1;
- DIV
- days in vitro;
- GEF
- guanine nucleotide exchange factor;
- GFP
- green fluorescent protein;
- PBS
- phosphate-buffered saline
Acknowledgments
We thank Tallie Baram for her helpful discussion on this study. This work was supported by grants from the Medical Research Council, MR/L021064/1, Royal Society UK (Grant RG130856), and the Brain and Behavior Foundation (formally National Alliance for Research on Schizophrenia and Depression (NARSAD); Grant No. 25957), awarded to D.P.S.; and NIH grants R01MH071316 and R01MH097216 to P.P.